Index: qrda/C0Q/trunk/kids/C0QDATA_1_0_0_T1.KID
===================================================================
--- qrda/C0Q/trunk/kids/C0QDATA_1_0_0_T1.KID	(revision 1362)
+++ qrda/C0Q/trunk/kids/C0QDATA_1_0_0_T1.KID	(revision 1362)
@@ -0,0 +1,1894 @@
+KIDS Distribution saved on Feb 17, 2012@16:48:29
+only the C0Q QUALITY MEASURE file with data
+**KIDS**:C0QDATA*1.0*1^
+
+**INSTALL NAME**
+C0QDATA*1.0*1
+"BLD",7923,0)
+C0QDATA*1.0*1^^0^3120217^n
+"BLD",7923,4,0)
+^9.64PA^1130580001.101^1
+"BLD",7923,4,1130580001.101,0)
+1130580001.101
+"BLD",7923,4,1130580001.101,222)
+y^y^f^^n^^y^m^y
+"BLD",7923,4,"B",1130580001.101,1130580001.101)
+
+"BLD",7923,6.3)
+1
+"BLD",7923,"KRN",0)
+^9.67PA^779.2^20
+"BLD",7923,"KRN",.4,0)
+.4
+"BLD",7923,"KRN",.401,0)
+.401
+"BLD",7923,"KRN",.402,0)
+.402
+"BLD",7923,"KRN",.403,0)
+.403
+"BLD",7923,"KRN",.5,0)
+.5
+"BLD",7923,"KRN",.84,0)
+.84
+"BLD",7923,"KRN",3.6,0)
+3.6
+"BLD",7923,"KRN",3.8,0)
+3.8
+"BLD",7923,"KRN",9.2,0)
+9.2
+"BLD",7923,"KRN",9.8,0)
+9.8
+"BLD",7923,"KRN",19,0)
+19
+"BLD",7923,"KRN",19.1,0)
+19.1
+"BLD",7923,"KRN",101,0)
+101
+"BLD",7923,"KRN",409.61,0)
+409.61
+"BLD",7923,"KRN",771,0)
+771
+"BLD",7923,"KRN",779.2,0)
+779.2
+"BLD",7923,"KRN",870,0)
+870
+"BLD",7923,"KRN",8989.51,0)
+8989.51
+"BLD",7923,"KRN",8989.52,0)
+8989.52
+"BLD",7923,"KRN",8994,0)
+8994
+"BLD",7923,"KRN","B",.4,.4)
+
+"BLD",7923,"KRN","B",.401,.401)
+
+"BLD",7923,"KRN","B",.402,.402)
+
+"BLD",7923,"KRN","B",.403,.403)
+
+"BLD",7923,"KRN","B",.5,.5)
+
+"BLD",7923,"KRN","B",.84,.84)
+
+"BLD",7923,"KRN","B",3.6,3.6)
+
+"BLD",7923,"KRN","B",3.8,3.8)
+
+"BLD",7923,"KRN","B",9.2,9.2)
+
+"BLD",7923,"KRN","B",9.8,9.8)
+
+"BLD",7923,"KRN","B",19,19)
+
+"BLD",7923,"KRN","B",19.1,19.1)
+
+"BLD",7923,"KRN","B",101,101)
+
+"BLD",7923,"KRN","B",409.61,409.61)
+
+"BLD",7923,"KRN","B",771,771)
+
+"BLD",7923,"KRN","B",779.2,779.2)
+
+"BLD",7923,"KRN","B",870,870)
+
+"BLD",7923,"KRN","B",8989.51,8989.51)
+
+"BLD",7923,"KRN","B",8989.52,8989.52)
+
+"BLD",7923,"KRN","B",8994,8994)
+
+"DATA",1130580001.101,1,0)
+M1^41^40^2.16.840.1.113883.3.249.11.2
+"DATA",1130580001.101,1,1)
+CMS Measure #1: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
+"DATA",1130580001.101,1,4)
+PQRI-1
+"DATA",1130580001.101,1,5)
+Hemoglobin A1c Poor Control in Diabetes Mellitus
+"DATA",1130580001.101,1,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,1,6,1,0)
+Percentage of patients 18 through 75 years with diabetes melli
+"DATA",1130580001.101,1,6,2,0)
+tus who had most recent hemoglobin A1C greater than 9.0%
+"DATA",1130580001.101,2,0)
+M5^47^46^2.16.840.1.113883.3.249.11.5
+"DATA",1130580001.101,2,1)
+CMS Measure #5: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
+"DATA",1130580001.101,2,4)
+PQRI-5
+"DATA",1130580001.101,2,5)
+Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
+"DATA",1130580001.101,2,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,2,6,1,0)
+Percentage of patients 18 years and older with a diagnosis of 
+"DATA",1130580001.101,2,6,2,0)
+heart failure and LVSD who were prescribed an ACE inhbitor or ARB therapy
+"DATA",1130580001.101,3,0)
+M112^26^25^2.16.840.1.113883.3.249.11.9
+"DATA",1130580001.101,3,1)
+Measure #112: Preventive Care and Screening: Screening Mammography
+"DATA",1130580001.101,3,4)
+PQRI-112
+"DATA",1130580001.101,3,5)
+Screening Mammography
+"DATA",1130580001.101,3,6,0)
+^1130580001.111^2^2^3101014^^
+"DATA",1130580001.101,3,6,1,0)
+Percentage of womaen aged 40 through 69 years who had a mammog
+"DATA",1130580001.101,3,6,2,0)
+ram to screen for breast cancer within 24 months
+"DATA",1130580001.101,4,0)
+M124^33^33^2.16.840.1.113883.3.249.11.11
+"DATA",1130580001.101,4,1)
+Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
+"DATA",1130580001.101,4,4)
+PQRI-124
+"DATA",1130580001.101,4,5)
+Adoption/Use of Electronic Health Records (EHR)
+"DATA",1130580001.101,4,6,0)
+^^3^3^3101013^
+"DATA",1130580001.101,4,6,1,0)
+Documents whether provider has adopted and is using health inf
+"DATA",1130580001.101,4,6,2,0)
+ormation technology. To qualify, the provider must havea adopted and be 
+"DATA",1130580001.101,4,6,3,0)
+using a certified/qualified electronic health record (EHR)
+"DATA",1130580001.101,5,0)
+M128^58^31^2.16.840.1.113883.3.249.11.54
+"DATA",1130580001.101,5,1)
+Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
+"DATA",1130580001.101,5,4)
+PQRI-128
+"DATA",1130580001.101,5,5)
+Body Mass Index (BMI) Screening and Follow-Up
+"DATA",1130580001.101,5,6,0)
+^1130580001.111^5^5^3101014^^
+"DATA",1130580001.101,5,6,1,0)
+Percentage of patients aged 18 yesrs and older with a calculate BMI in 
+"DATA",1130580001.101,5,6,2,0)
+the past 6 months or during the current visit documented in the medical 
+"DATA",1130580001.101,5,6,3,0)
+record and if the most recent BMI is ourtide parameters, a follow-up plan 
+"DATA",1130580001.101,5,6,4,0)
+is documented. Ages 65 and older BMI equal to or greater than 30 or less 
+"DATA",1130580001.101,5,6,5,0)
+than 22 and ages 18-64, BMI greater than or equal to 25 or less than 18.5
+"DATA",1130580001.101,6,0)
+M47^20^48^2.16.840.1.113883.3.249.11.52
+"DATA",1130580001.101,6,1)
+Measure #47: Advance Care Plan
+"DATA",1130580001.101,6,4)
+PQRI-47
+"DATA",1130580001.101,6,5)
+Advance Care Plan
+"DATA",1130580001.101,6,6,0)
+^1130580001.111^5^5^3101014^^^
+"DATA",1130580001.101,6,6,1,0)
+Percentage of patients age 65 and older who have an advanced care plan or 
+"DATA",1130580001.101,6,6,2,0)
+surrogate decision maker documented in the medical record or documented 
+"DATA",1130580001.101,6,6,3,0)
+in the medical record that an advance care plan was discussed but the 
+"DATA",1130580001.101,6,6,4,0)
+patient did not wish or was not able to name a surrogate decision maker 
+"DATA",1130580001.101,6,6,5,0)
+or provide an advance care plan.
+"DATA",1130580001.101,7,0)
+M48^24^23^2.16.840.1.113883.3.249.11.53
+"DATA",1130580001.101,7,1)
+Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
+"DATA",1130580001.101,7,4)
+PQRI-48
+"DATA",1130580001.101,7,5)
+Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
+"DATA",1130580001.101,7,6,0)
+^^3^3^3101013^
+"DATA",1130580001.101,7,6,1,0)
+Percentage of patients equal to or older than 65 years of age at the 
+"DATA",1130580001.101,7,6,2,0)
+beginning of the measurement perion who were assesed for the presence or 
+"DATA",1130580001.101,7,6,3,0)
+absence of urinary incontinence within 12 months
+"DATA",1130580001.101,8,0)
+M2^43^42^2.16.840.1.113883.3.249.11.3
+"DATA",1130580001.101,8,1)
+Measure #2: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
+"DATA",1130580001.101,8,4)
+PQRI-2
+"DATA",1130580001.101,8,5)
+Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
+"DATA",1130580001.101,8,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,8,6,1,0)
+Percentage of patients 18 through 75 years with diabetes melli
+"DATA",1130580001.101,8,6,2,0)
+tus who had most recent LDL-C level in control (less than 100 mg./dL)
+"DATA",1130580001.101,9,0)
+M3^45^44^2.16.840.1.113883.3.249.11.4
+"DATA",1130580001.101,9,1)
+CMS Measure #3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus - QRDA Cat I template
+"DATA",1130580001.101,9,4)
+PQRI-3
+"DATA",1130580001.101,9,5)
+High Blood Pressure Control in Diabetes Mellitus
+"DATA",1130580001.101,9,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,9,6,1,0)
+Percentage of patients 18 through 75 years with diabetes melli
+"DATA",1130580001.101,9,6,2,0)
+tus who had most recent blood pressure in control (less than 140/80 mmHg)
+"DATA",1130580001.101,10,0)
+M7^35^34^2.16.840.1.113883.3.249.11.6
+"DATA",1130580001.101,10,1)
+CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
+"DATA",1130580001.101,10,4)
+PQRI-7
+"DATA",1130580001.101,10,5)
+Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
+"DATA",1130580001.101,10,6,0)
+^^3^3^3101013^
+"DATA",1130580001.101,10,6,1,0)
+Percentage of patients aged 18 years and older with a diagnosis of 
+"DATA",1130580001.101,10,6,2,0)
+coronary artery disease and a prior MI who where prescribed beta-blocker 
+"DATA",1130580001.101,10,6,3,0)
+therapy
+"DATA",1130580001.101,11,0)
+M110^81^80^2.16.840.1.113883.3.249.11.7
+"DATA",1130580001.101,11,1)
+Measure #110: Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years
+"DATA",1130580001.101,11,4)
+PQRI-110
+"DATA",1130580001.101,11,5)
+Influenza Immunization for Patients >= 50 Years
+"DATA",1130580001.101,11,6,0)
+^1130580001.111^2^2^3101014^^
+"DATA",1130580001.101,11,6,1,0)
+Percentage of patients aged 50 years and older who received an
+"DATA",1130580001.101,11,6,2,0)
+ influenza immunization during the flu season (September through February)
+"DATA",1130580001.101,12,0)
+M111^71^68^2.16.840.1.113883.3.249.11.8
+"DATA",1130580001.101,12,1)
+Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
+"DATA",1130580001.101,12,4)
+PQRI-111
+"DATA",1130580001.101,12,5)
+Pneumonia Vaccination for Patients 65 Years and Older
+"DATA",1130580001.101,12,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,12,6,1,0)
+Percentage of patients afed 65 years and older who have ever r
+"DATA",1130580001.101,12,6,2,0)
+eceived a pneumoccal vaccine
+"DATA",1130580001.101,13,0)
+M113^67^66^2.16.840.1.113883.3.249.11.10
+"DATA",1130580001.101,13,1)
+Measure #113: Preventive Care and Screening: Colorectal Cancer Screening
+"DATA",1130580001.101,13,4)
+PQRI-113
+"DATA",1130580001.101,13,5)
+Colorectal Cancer Screening
+"DATA",1130580001.101,13,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,13,6,1,0)
+Percentage of patients aged 50 through 80 who received the app
+"DATA",1130580001.101,13,6,2,0)
+ropriate colorectal cancer screening
+"DATA",1130580001.101,14,0)
+M39^65^64^2.16.840.1.113883.3.249.11.51
+"DATA",1130580001.101,14,1)
+Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
+"DATA",1130580001.101,14,4)
+PQRI-39
+"DATA",1130580001.101,14,5)
+Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
+"DATA",1130580001.101,14,6,0)
+^^3^3^3101013^
+"DATA",1130580001.101,14,6,1,0)
+Percentage of patients who had a DXA measurement ordered or pe
+"DATA",1130580001.101,14,6,2,0)
+rformed at least once since age 60 or pharmacologic therapy prescribed 
+"DATA",1130580001.101,14,6,3,0)
+within 12 months before the end of the measurement period
+"DATA",1130580001.101,16,0)
+M173^50^49^2.16.840.1.113883.3.249.11.55
+"DATA",1130580001.101,16,1)
+Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
+"DATA",1130580001.101,16,4)
+PQRI-173
+"DATA",1130580001.101,16,5)
+Preventive Care and Screening: Unhealthy Alcohol Use - Screening
+"DATA",1130580001.101,16,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,16,6,1,0)
+Percentage of patients aged 18 years and older who were screen
+"DATA",1130580001.101,16,6,2,0)
+ed for unhealthy alcohol use using a systematic method within 24 months
+"DATA",1130580001.101,17,0)
+M0013^52^77^2.16.840.1.113883.3.249.11.56
+"DATA",1130580001.101,17,1)
+Measure #0013: Hypertension (HTN): Blood Pressure Measurement - QRDA Cat I template
+"DATA",1130580001.101,17,4)
+PQRI-13
+"DATA",1130580001.101,17,5)
+Hypertension (HTN): Blood Pressure Measurement
+"DATA",1130580001.101,17,6,0)
+^1130580001.111^3^3^3110412^^
+"DATA",1130580001.101,17,6,1,0)
+Percentage of patients aged 18 years and older with a diagnosi
+"DATA",1130580001.101,17,6,2,0)
+s of hypertension in the beginning of the measurement period with a blood 
+"DATA",1130580001.101,17,6,3,0)
+pressure recorded
+"DATA",1130580001.101,18,0)
+M0022^73^61^2.16.840.1.113883.3.249.11.57
+"DATA",1130580001.101,18,1)
+Measure #0022: Drugs to be avoided in the Elderly
+"DATA",1130580001.101,18,4)
+PQRI-22
+"DATA",1130580001.101,18,5)
+Drugs to be avoided in the elderly
+"DATA",1130580001.101,18,6,0)
+^^2^2^3101013^
+"DATA",1130580001.101,18,6,1,0)
+Percentage of patients aged 65 years and older who received at least one 
+"DATA",1130580001.101,18,6,2,0)
+drug to be avoided in the elderly in the measurement period
+"DATA",1130580001.101,19,0)
+M0028^79^78^2.16.840.1.113883.3.249.11.59
+"DATA",1130580001.101,19,1)
+Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
+"DATA",1130580001.101,19,4)
+PQRI-28
+"DATA",1130580001.101,19,5)
+Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
+"DATA",1130580001.101,19,6,0)
+^^4^4^3101013^
+"DATA",1130580001.101,19,6,1,0)
+Percentage of patients aged 18 years of older who were screene
+"DATA",1130580001.101,19,6,2,0)
+d about tobacco use at least once during the two year measurement period 
+"DATA",1130580001.101,19,6,3,0)
+AND who received smoking cessation counseling if identified as a tobacco 
+"DATA",1130580001.101,19,6,4,0)
+user
+"DATA",1130580001.101,20,0)
+M0038^85^84^2.16.840.1.113883.3.249.11.60
+"DATA",1130580001.101,20,1)
+Measure #0038: Childhood Immunization Status
+"DATA",1130580001.101,20,4)
+PQRI-38
+"DATA",1130580001.101,20,5)
+Childhood immumnization status
+"DATA",1130580001.101,20,6,0)
+^^4^4^3101013^
+"DATA",1130580001.101,20,6,1,0)
+Percentage of children who turn two years of age during the me
+"DATA",1130580001.101,20,6,2,0)
+asurement period who have had 4 DTaP/DT, 3 IPV, 1 MMR and 3 H influenza 
+"DATA",1130580001.101,20,6,3,0)
+type B, 3 hepatitis B, 1 chicken pox vaccine (VZV) and 4 pneumoccal 
+"DATA",1130580001.101,20,6,4,0)
+conjugate vaccines by their second birthday
+"DATA",1130580001.101,21,0)
+M0024^72^70
+"DATA",1130580001.101,22,0)
+TEST M0028A^107^106^2.16.840.1.113883.3.249.11.59
+"DATA",1130580001.101,22,1)
+Measure #0028: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
+"DATA",1130580001.101,22,4)
+PQRI-28
+"DATA",1130580001.101,22,5)
+Preventive care and Screening: Tobacco Use: Screening and Cessation Intervention
+"DATA",1130580001.101,22,6,0)
+^1130580001.111^4^4^3110427^^^^
+"DATA",1130580001.101,22,6,1,0)
+Percentage of patients aged 18 years of older who were screene
+"DATA",1130580001.101,22,6,2,0)
+d about tobacco use at least once during the two year measurement period 
+"DATA",1130580001.101,22,6,3,0)
+AND who received smoking cessation counseling if identified as a tobacco 
+"DATA",1130580001.101,22,6,4,0)
+user
+"DATA",1130580001.101,23,0)
+MU HOS NQF 0495^53^135
+"DATA",1130580001.101,23,1)
+ED THROUGHPUT ARRIVAL TO DEPARTURE
+"DATA",1130580001.101,23,5)
+ED THROUGHPUT ARRIVAL TO DEPARTURE
+"DATA",1130580001.101,23,6,0)
+^1130580001.111^3^3^3110430^^^^
+"DATA",1130580001.101,23,6,1,0)
+Median time from emergency department arrival to time of departure from 
+"DATA",1130580001.101,23,6,2,0)
+the emergency room for patients admitted to the facility from the
+"DATA",1130580001.101,23,6,3,0)
+emergency department
+"DATA",1130580001.101,23,7)
+NQF0495
+"DATA",1130580001.101,24,0)
+MU HOS NQF 0497^54^94
+"DATA",1130580001.101,24,1)
+ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
+"DATA",1130580001.101,24,5)
+ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
+"DATA",1130580001.101,24,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,24,6,1,0)
+Median time from admit decision time to time of departure from the 
+"DATA",1130580001.101,24,6,2,0)
+emergency department of emergency department patients admitted to 
+"DATA",1130580001.101,24,6,3,0)
+inpatient status
+"DATA",1130580001.101,24,7)
+NQF0497
+"DATA",1130580001.101,25,0)
+MU HOS NQF 0435^55^56
+"DATA",1130580001.101,25,1)
+Ischemic stroke.Discharge on anti-thrombotics  
+"DATA",1130580001.101,25,5)
+ Ischemic stroke.Discharge on anti-thrombotic
+"DATA",1130580001.101,25,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,25,6,1,0)
+Ischemic stroke patients prescribed antithrombotic therapy at hospital 
+"DATA",1130580001.101,25,6,2,0)
+discharge
+"DATA",1130580001.101,25,7)
+NQF0435
+"DATA",1130580001.101,26,0)
+MU HOS NQF 0436^57^58
+"DATA",1130580001.101,26,1)
+ Ischemic stroke.Anticoagulation for A-fib/flutter
+"DATA",1130580001.101,26,5)
+Ischemic stroke.Anticoagulation for A-fib/flutter
+"DATA",1130580001.101,26,6,0)
+^1130580001.111^2^2^3110430^^^
+"DATA",1130580001.101,26,6,1,0)
+ Ischemic stroke patients with atrial fibrillation/flutter who are 
+"DATA",1130580001.101,26,6,2,0)
+prescribed anticoagulation therapy at hospital discharge
+"DATA",1130580001.101,26,7)
+NQF0436
+"DATA",1130580001.101,27,0)
+MU HOS NQF 0437^59^60
+"DATA",1130580001.101,27,1)
+ Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
+"DATA",1130580001.101,27,5)
+Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
+"DATA",1130580001.101,27,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,27,6,1,0)
+Acute ischemic stroke patients who arrive at this hospital within 2 
+"DATA",1130580001.101,27,6,2,0)
+hours of time last known well and for whom IV t-PA was initiated at this 
+"DATA",1130580001.101,27,6,3,0)
+hospital within 3 hours of time last known well.
+"DATA",1130580001.101,27,7)
+NQF0437
+"DATA",1130580001.101,28,0)
+MU HOS NQF 0438^61^62
+"DATA",1130580001.101,28,1)
+Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
+"DATA",1130580001.101,28,5)
+Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
+"DATA",1130580001.101,28,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,28,6,1,0)
+Ischemic stroke patients administered antithrombotic therapy by the 
+"DATA",1130580001.101,28,6,2,0)
+end of hospital day 2.
+"DATA",1130580001.101,28,7)
+NQF0438
+"DATA",1130580001.101,29,0)
+MU HOS NQF 0439^63^64
+"DATA",1130580001.101,29,1)
+Ischemic stroke.Discharge on statins
+"DATA",1130580001.101,29,5)
+Ischemic stroke.Discharge on statins
+"DATA",1130580001.101,29,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,29,6,1,0)
+Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or, 
+"DATA",1130580001.101,29,6,2,0)
+who were on a lipid-lowering medication prior to hospital arrival are
+"DATA",1130580001.101,29,6,3,0)
+prescribed statin medication at hospital discharge
+"DATA",1130580001.101,29,7)
+NQF0439
+"DATA",1130580001.101,30,0)
+MU HOS NQF 0440^65^66
+"DATA",1130580001.101,30,1)
+Ischemic or hemorrhagic stroke.Stroke education
+"DATA",1130580001.101,30,5)
+Ischemic or hemorrhagic stroke.Stroke education
+"DATA",1130580001.101,30,6,0)
+^^5^5^3110430^
+"DATA",1130580001.101,30,6,1,0)
+Ischemic or hemorrhagic stroke patients or their caregivers who were 
+"DATA",1130580001.101,30,6,2,0)
+given educational materials during the hospital stay addressing all of the
+"DATA",1130580001.101,30,6,3,0)
+following: activation of emergency medical system, need for follow-up
+"DATA",1130580001.101,30,6,4,0)
+after discharge, medications prescribed at discharge, risk factors for
+"DATA",1130580001.101,30,6,5,0)
+stroke, and warning signs and symptoms of stroke.
+"DATA",1130580001.101,30,7)
+NQF0440
+"DATA",1130580001.101,31,0)
+MU HOS NQF 0441^67^68
+"DATA",1130580001.101,31,1)
+Ischemic or hemorrhagic stroke.Rehabilitation assessment
+"DATA",1130580001.101,31,5)
+Ischemic or hemorrhagic stroke.Rehabilitation assessment
+"DATA",1130580001.101,31,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,31,6,1,0)
+Ischemic or hemorrhagic stroke patients who were assessed for 
+"DATA",1130580001.101,31,6,2,0)
+rehabilitation services.
+"DATA",1130580001.101,31,7)
+NQF0441
+"DATA",1130580001.101,32,0)
+MU HOS NQF 0371^44^43
+"DATA",1130580001.101,32,1)
+VTE prophylaxis within 24 hours of arrival  
+"DATA",1130580001.101,32,5)
+VTE prophylaxis within 24 hours of arrival  
+"DATA",1130580001.101,32,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,32,6,1,0)
+This measure assesses the number of patients who received VTE prophylaxis 
+"DATA",1130580001.101,32,6,2,0)
+or have documentation why no VTE prophylaxis was given the day of or the 
+"DATA",1130580001.101,32,6,3,0)
+day after hospital admission or surgery end date for surgeries that start
+"DATA",1130580001.101,32,6,4,0)
+the day of or the day after hospital admission.
+"DATA",1130580001.101,32,7)
+NQF0371
+"DATA",1130580001.101,33,0)
+MU HOS NQF 0372^69^45
+"DATA",1130580001.101,33,1)
+ICU VTE prophylaxis  
+"DATA",1130580001.101,33,5)
+ICU VTE prophylaxis
+"DATA",1130580001.101,33,6,0)
+^^5^5^3110430^
+"DATA",1130580001.101,33,6,1,0)
+This measure assesses the number of patients who received VTE prophylaxis 
+"DATA",1130580001.101,33,6,2,0)
+or have documentation why no VTE prophylaxis was given the day of or the 
+"DATA",1130580001.101,33,6,3,0)
+day after the initial admission (or transfer) to the Intensive Care Unit
+"DATA",1130580001.101,33,6,4,0)
+(ICU) or surgery end date for surgeries that start the day of or the day
+"DATA",1130580001.101,33,6,5,0)
+after ICU admission (or transfer).
+"DATA",1130580001.101,33,7)
+NQF0372
+"DATA",1130580001.101,34,0)
+MU HOS NQF 0373^70^71
+"DATA",1130580001.101,34,1)
+Anticoagulation overlap therapy  
+"DATA",1130580001.101,34,5)
+Anticoagulation overlap therapy
+"DATA",1130580001.101,34,6,0)
+^^8^8^3110430^
+"DATA",1130580001.101,34,6,1,0)
+This measure assesses the number of patients diagnosed with confirmed VTE 
+"DATA",1130580001.101,34,6,2,0)
+who received an overlap of parenteral (intravenous [IV] or subcutaneous 
+"DATA",1130580001.101,34,6,3,0)
+[subcu]) anticoagulation and warfarin therapy. For patients who received
+"DATA",1130580001.101,34,6,4,0)
+less than five days of overlap therapy, they must be discharged on both
+"DATA",1130580001.101,34,6,5,0)
+medications. Overlap therapy must be administered for at least five days
+"DATA",1130580001.101,34,6,6,0)
+with an international normalized ratio (INR) . 2 prior to discontinuation
+"DATA",1130580001.101,34,6,7,0)
+of the parenteral anticoagulation therapy or the patient must be
+"DATA",1130580001.101,34,6,8,0)
+discharged on both medications.
+"DATA",1130580001.101,34,7)
+NQF0373
+"DATA",1130580001.101,35,0)
+MU HOS NQF 0374^72^73
+"DATA",1130580001.101,35,1)
+Platelet monitoring on unfractionated heparin
+"DATA",1130580001.101,35,5)
+Platelet monitoring on unfractionated heparin
+"DATA",1130580001.101,35,6,0)
+^^10^10^3110430^
+"DATA",1130580001.101,35,6,1,0)
+This measure assesses the number of patients diagnosed with confirmed VTE 
+"DATA",1130580001.101,35,6,2,0)
+who received intravenous (IV) UFH therapy dosages AND had their platelet 
+"DATA",1130580001.101,35,6,3,0)
+counts monitored using defined parameters such as a nomogram or
+"DATA",1130580001.101,35,6,4,0)
+protocol This measure assesses the number of patients diagnosed with
+"DATA",1130580001.101,35,6,5,0)
+confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
+"DATA",1130580001.101,35,6,6,0)
+their platelet counts monitored using defined parameters such as a
+"DATA",1130580001.101,35,6,7,0)
+nomogram or protocol This measure assesses the number of patients
+"DATA",1130580001.101,35,6,8,0)
+diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
+"DATA",1130580001.101,35,6,9,0)
+dosages AND had their platelet counts monitored using defined parameters
+"DATA",1130580001.101,35,6,10,0)
+such as a nomogram or protocol
+"DATA",1130580001.101,35,7)
+NQF0374
+"DATA",1130580001.101,36,0)
+MU HOS NQF 0375^74^75
+"DATA",1130580001.101,36,1)
+VTE discharge instructions
+"DATA",1130580001.101,36,5)
+VTE discharge instructions
+"DATA",1130580001.101,36,6,0)
+^^11^11^3110430^
+"DATA",1130580001.101,36,6,1,0)
+This measure assesses the number of patients diagnosed with confirmed VTE 
+"DATA",1130580001.101,36,6,2,0)
+that are discharged to home, to home with home health, home hospice or 
+"DATA",1130580001.101,36,6,3,0)
+discharged/transferred to court/law enforcement on warfarin with written 
+"DATA",1130580001.101,36,6,4,0)
+discharge instructions that address all four criteria: compliance issues,
+"DATA",1130580001.101,36,6,5,0)
+dietary advice, follow-up This measure assesses the number of patients
+"DATA",1130580001.101,36,6,6,0)
+diagnosed with confirmed VTE that are discharged to home, to home with
+"DATA",1130580001.101,36,6,7,0)
+home health, home hospice or discharged/transferred to court/law
+"DATA",1130580001.101,36,6,8,0)
+enforcement on warfarin with written discharge instructions that address
+"DATA",1130580001.101,36,6,9,0)
+all four criteria: compliance issues, dietary advice, follow-up
+"DATA",1130580001.101,36,6,10,0)
+monitoring, and information about the potential for adverse drug 
+"DATA",1130580001.101,36,6,11,0)
+reactions/interactions.
+"DATA",1130580001.101,36,7)
+NQF0375
+"DATA",1130580001.101,37,0)
+MU HOS NQF 0376^76^77
+"DATA",1130580001.101,37,1)
+Incidence of potentially preventable VTE
+"DATA",1130580001.101,37,5)
+Incidence of potentially preventable VTE
+"DATA",1130580001.101,37,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,37,6,1,0)
+This measure assesses the number of patients diagnosed with confirmed VTE 
+"DATA",1130580001.101,37,6,2,0)
+during hospitalization (not present on arrival) who did not receive VTE 
+"DATA",1130580001.101,37,6,3,0)
+prophylaxis between hospital admission and the day before the VTE
+"DATA",1130580001.101,37,6,4,0)
+diagnostic testing order date.
+"DATA",1130580001.101,37,7)
+NQF0376
+"DATA",1130580001.101,38,0)
+12
+"DATA",1130580001.101,39,0)
+MU EP NQF 0421^156^152
+"DATA",1130580001.101,39,1)
+NQF0421 Adult Weight Screening and Follow-Up
+"DATA",1130580001.101,39,5)
+NQF0421 Adult Weight Screening and Follow-Up
+"DATA",1130580001.101,39,6,0)
+^1130580001.111^6^6^3110628^^^^
+"DATA",1130580001.101,39,6,1,0)
+Percentage of patients aged 18 
+"DATA",1130580001.101,39,6,2,0)
+years and older with a calculated BMI in the past 
+"DATA",1130580001.101,39,6,3,0)
+six months or during the current visit documented in 
+"DATA",1130580001.101,39,6,4,0)
+the medical record AND if the most recent BMI is 
+"DATA",1130580001.101,39,6,5,0)
+outside parameters, a follow-up plan is 
+"DATA",1130580001.101,39,6,6,0)
+documented.
+"DATA",1130580001.101,39,7)
+NQF0421
+"DATA",1130580001.101,40,0)
+MU EP NQF 0013^99^40
+"DATA",1130580001.101,40,1)
+NQF0013 Hypertension: Blood Pressure Measurement
+"DATA",1130580001.101,40,5)
+NQF0013 Hypertension: Blood Pressure Measurement
+"DATA",1130580001.101,40,6,0)
+^1130580001.111^4^4^3110628^^
+"DATA",1130580001.101,40,6,1,0)
+Percentage of patient visits for patients  
+"DATA",1130580001.101,40,6,2,0)
+aged 18 years and older with a diagnosis of hypertension 
+"DATA",1130580001.101,40,6,3,0)
+who have been seen for at least 2 office visits, with blood 
+"DATA",1130580001.101,40,6,4,0)
+pressure (BP) recorded
+"DATA",1130580001.101,40,7)
+NQF0013
+"DATA",1130580001.101,41,0)
+MU EP NQF 0028A^102^100
+"DATA",1130580001.101,41,1)
+NQF0028A Preventive Care and Screening  Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention 
+"DATA",1130580001.101,41,5)
+NQF0028A Tobacco Use Assessment
+"DATA",1130580001.101,41,6,0)
+^1130580001.111^7^7^3110625^^^
+"DATA",1130580001.101,41,6,1,0)
+ Percentage of patients aged 18 years and  
+"DATA",1130580001.101,41,6,2,0)
+older who have been seen for at least 2 office visits who 
+"DATA",1130580001.101,41,6,3,0)
+were queried about tobacco use one or more times within 
+"DATA",1130580001.101,41,6,4,0)
+24 months  b. Percentage of patients aged 18 years and 
+"DATA",1130580001.101,41,6,5,0)
+older  identified as tobacco users within the past 24 
+"DATA",1130580001.101,41,6,6,0)
+months and have been seen for at least 2 office visits, 
+"DATA",1130580001.101,41,6,7,0)
+who received cessation intervention.
+"DATA",1130580001.101,41,7)
+NQF0028A
+"DATA",1130580001.101,42,0)
+MU EP NQF 0041^144^132
+"DATA",1130580001.101,42,1)
+Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old 
+"DATA",1130580001.101,42,5)
+NQF0041 Influenza Immunization 50 years and older
+"DATA",1130580001.101,42,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,42,6,1,0)
+Percentage of patients aged 50 years 
+"DATA",1130580001.101,42,6,2,0)
+and older who received an influenza immunization 
+"DATA",1130580001.101,42,6,3,0)
+during the flu season (September through 
+"DATA",1130580001.101,42,6,4,0)
+February). 
+"DATA",1130580001.101,42,7)
+NQF0041
+"DATA",1130580001.101,43,0)
+MU EP NQF 0024^42^41
+"DATA",1130580001.101,43,1)
+NQF0024 Weight Assessment and Counseling for Children and Adolescents
+"DATA",1130580001.101,43,5)
+NQF0024 Weight Assessment and Counseling for Children and Adolescents 
+"DATA",1130580001.101,43,6,0)
+^^6^6^3110430^
+"DATA",1130580001.101,43,6,1,0)
+Percentage of patients 2 -17 years of age 
+"DATA",1130580001.101,43,6,2,0)
+who had an outpatient visit with a Primary Care Physician 
+"DATA",1130580001.101,43,6,3,0)
+(PCP) or OB/GYN and who had evidence of BMI 
+"DATA",1130580001.101,43,6,4,0)
+percentile documentation, counseling for nutrition and 
+"DATA",1130580001.101,43,6,5,0)
+counseling for physical activity during the measurement 
+"DATA",1130580001.101,43,6,6,0)
+year.
+"DATA",1130580001.101,43,7)
+NQF0024
+"DATA",1130580001.101,44,0)
+MU EP NQF 0038
+"DATA",1130580001.101,44,1)
+Childhood Immunization Status
+"DATA",1130580001.101,44,5)
+Childhood Immunization Status
+"DATA",1130580001.101,44,6,0)
+^^14^14^3110430^
+"DATA",1130580001.101,44,6,1,0)
+Percentage of children 2 years of age who 
+"DATA",1130580001.101,44,6,2,0)
+had four diphtheria, tetanus and acellular  pertussis 
+"DATA",1130580001.101,44,6,3,0)
+(DTaP); three polio(IPV), one measles, ,mumps and 
+"DATA",1130580001.101,44,6,4,0)
+rubella (MMR); two H influenza type B (HiB); three 
+"DATA",1130580001.101,44,6,5,0)
+Percentage of children 2 years of age who 
+"DATA",1130580001.101,44,6,6,0)
+had four diphtheria, tetanus and acellular  pertussis 
+"DATA",1130580001.101,44,6,7,0)
+(DTaP); three polio(IPV), one measles, ,mumps and 
+"DATA",1130580001.101,44,6,8,0)
+rubella (MMR); two H influenza type B (HiB); three 
+"DATA",1130580001.101,44,6,9,0)
+hepatitis B (Hep B); one chicken pox (VZV); four 
+"DATA",1130580001.101,44,6,10,0)
+pneumococcal conjugate (PCV); two hepatitis A (Hep A); 
+"DATA",1130580001.101,44,6,11,0)
+two or three rotavirus (RV); and two influenza (flu) 
+"DATA",1130580001.101,44,6,12,0)
+vaccines by their second birthday. The measure 
+"DATA",1130580001.101,44,6,13,0)
+calculates a rate for each vaccine and nine separate 
+"DATA",1130580001.101,44,6,14,0)
+combination rates.
+"DATA",1130580001.101,44,7)
+NQF0038
+"DATA",1130580001.101,45,0)
+MU EP NQF 0059^146^145
+"DATA",1130580001.101,45,1)
+Diabetes: Hemoglobin A1c Poor Contro
+"DATA",1130580001.101,45,5)
+Diabetes: NQF0059 Hemoglobin A1c Poor Control
+"DATA",1130580001.101,45,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,45,6,1,0)
+Percentage of patients 18 - 75 years of age with diabetes (type 1 
+"DATA",1130580001.101,45,6,2,0)
+or type 2) who had hemoglobin A1c > 9.0%.
+"DATA",1130580001.101,45,7)
+NQF0059
+"DATA",1130580001.101,46,0)
+MU EP NQF 0064^139^145
+"DATA",1130580001.101,46,1)
+Diabetes: Low Density Lipoprotein (LDL) Management and Control  
+"DATA",1130580001.101,46,5)
+NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control  
+"DATA",1130580001.101,46,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,46,6,1,0)
+Percentage of patients 18-75 years of age with diabetes (type 1 
+"DATA",1130580001.101,46,6,2,0)
+or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years 
+"DATA",1130580001.101,46,6,3,0)
+of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
+"DATA",1130580001.101,46,7)
+NQF0064
+"DATA",1130580001.101,47,0)
+MU EP NQF 0061^147^145
+"DATA",1130580001.101,47,1)
+Blood Pressure Management
+"DATA",1130580001.101,47,5)
+NQF0061 Diabetes: Blood Pressure Management
+"DATA",1130580001.101,47,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,47,6,1,0)
+Percentage of patients 18 - 75 years of age with 
+"DATA",1130580001.101,47,6,2,0)
+diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
+"DATA",1130580001.101,47,7)
+NQF0061
+"DATA",1130580001.101,48,0)
+MU EP NQF 0081
+"DATA",1130580001.101,48,1)
+Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 
+"DATA",1130580001.101,48,5)
+Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) 
+"DATA",1130580001.101,48,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,48,6,1,0)
+Percentage of patients aged 18 years and older with a 
+"DATA",1130580001.101,48,6,2,0)
+diagnosis of heart failure and LVSD (LVEF < 40%) who were 
+"DATA",1130580001.101,48,6,3,0)
+prescribed ACE inhibitor or ARB therapy
+"DATA",1130580001.101,48,7)
+NQF0081
+"DATA",1130580001.101,49,0)
+MU EP NQF 0070
+"DATA",1130580001.101,49,1)
+Pneumonia Vaccination Status for Older Adults
+"DATA",1130580001.101,49,5)
+Pneumonia Vaccination Status for Older Adults
+"DATA",1130580001.101,49,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,49,6,1,0)
+Percentage of patients 65 years of age and older who have ever 
+"DATA",1130580001.101,49,6,2,0)
+received a pneumococcal vaccine.
+"DATA",1130580001.101,49,7)
+NQF0070
+"DATA",1130580001.101,50,0)
+MU EP NQF 0031
+"DATA",1130580001.101,50,1)
+Breast Cancer Screening
+"DATA",1130580001.101,50,5)
+Breast Cancer Screening
+"DATA",1130580001.101,50,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,50,6,1,0)
+Percentage of women 40-69 years of age who had a 
+"DATA",1130580001.101,50,6,2,0)
+mammogram to screen for breast cancer
+"DATA",1130580001.101,50,7)
+NQF0031
+"DATA",1130580001.101,51,0)
+MU EP NQF 0034
+"DATA",1130580001.101,51,1)
+Colorectal Cancer Screening
+"DATA",1130580001.101,51,5)
+Colorectal Cancer Screening
+"DATA",1130580001.101,51,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,51,6,1,0)
+Percentage of adults 50-75 years of age who had appropriate screening for
+"DATA",1130580001.101,51,6,2,0)
+colorectal cancer.
+"DATA",1130580001.101,51,7)
+NQF0034
+"DATA",1130580001.101,52,0)
+MU EP NQF 0067
+"DATA",1130580001.101,52,1)
+Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD 
+"DATA",1130580001.101,52,5)
+Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD 
+"DATA",1130580001.101,52,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,52,6,1,0)
+Percentage of patients aged 18 years  and older with a 
+"DATA",1130580001.101,52,6,2,0)
+diagnosis of CAD who were prescribed oral antiplatelet therapy.
+"DATA",1130580001.101,52,7)
+NQF0067
+"DATA",1130580001.101,53,0)
+MU EP NQF 0083
+"DATA",1130580001.101,53,1)
+Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) 
+"DATA",1130580001.101,53,5)
+Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
+"DATA",1130580001.101,53,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,53,6,1,0)
+Percentage of patients aged 18 years and older with a 
+"DATA",1130580001.101,53,6,2,0)
+diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were 
+"DATA",1130580001.101,53,6,3,0)
+prescribed beta-blocker therapy
+"DATA",1130580001.101,53,7)
+NQF0083
+"DATA",1130580001.101,54,0)
+MU EP NQF 0105
+"DATA",1130580001.101,54,1)
+Anti-depressant medication management:  (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment  
+"DATA",1130580001.101,54,5)
+Anti-depressant medication management:  (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment  
+"DATA",1130580001.101,54,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,54,6,1,0)
+The percentage of patients 18 years of age and older 
+"DATA",1130580001.101,54,6,2,0)
+who were diagnosed with a new episode of major depression, treated 
+"DATA",1130580001.101,54,6,3,0)
+with antidepressant medication, and who remained on an 
+"DATA",1130580001.101,54,6,4,0)
+antidepressant medication treatment.
+"DATA",1130580001.101,54,7)
+NQF0105
+"DATA",1130580001.101,55,0)
+MU EP NQF 0086
+"DATA",1130580001.101,55,1)
+Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
+"DATA",1130580001.101,55,5)
+Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
+"DATA",1130580001.101,55,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,55,6,1,0)
+Percentage of patients aged 18 years and older with a 
+"DATA",1130580001.101,55,6,2,0)
+diagnosis of POAG who have been seen for at least two office visits 
+"DATA",1130580001.101,55,6,3,0)
+who have an optic nerve head evaluation during one or more office 
+"DATA",1130580001.101,55,6,4,0)
+visits within 12 months.
+"DATA",1130580001.101,55,7)
+NQF0086
+"DATA",1130580001.101,56,0)
+MU EP NQF 0088
+"DATA",1130580001.101,56,1)
+Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy 
+"DATA",1130580001.101,56,5)
+Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy 
+"DATA",1130580001.101,56,6,0)
+^^5^5^3110430^
+"DATA",1130580001.101,56,6,1,0)
+Percentage of patients aged 18 years and older with a 
+"DATA",1130580001.101,56,6,2,0)
+diagnosis of diabetic retinopathy who had a dilated macular or fundus 
+"DATA",1130580001.101,56,6,3,0)
+exam performed which included documentation of the level of severity 
+"DATA",1130580001.101,56,6,4,0)
+of  retinopathy and the presence or absence of macular edema during 
+"DATA",1130580001.101,56,6,5,0)
+one or more office visits within 12 months.
+"DATA",1130580001.101,56,7)
+NQF0088
+"DATA",1130580001.101,57,0)
+MU EP NQF 0089
+"DATA",1130580001.101,57,1)
+Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care 
+"DATA",1130580001.101,57,5)
+Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care 
+"DATA",1130580001.101,57,6,0)
+^^6^6^3110430^
+"DATA",1130580001.101,57,6,1,0)
+Percentage of patients aged 18 years and older with a 
+"DATA",1130580001.101,57,6,2,0)
+diagnosis of diabetic retinopathy who had a dilated macular or fundus 
+"DATA",1130580001.101,57,6,3,0)
+exam performed with documented communication to the physician who 
+"DATA",1130580001.101,57,6,4,0)
+manages the ongoing care of the patient with diabetes mellitus 
+"DATA",1130580001.101,57,6,5,0)
+regarding the findings of the macular or fundus exam at least once 
+"DATA",1130580001.101,57,6,6,0)
+within 12 months.
+"DATA",1130580001.101,57,7)
+NQF0089
+"DATA",1130580001.101,58,0)
+MU EP NQF 0047
+"DATA",1130580001.101,58,1)
+Asthma Pharmacologic Therapy
+"DATA",1130580001.101,58,5)
+Asthma Pharmacologic Therapy
+"DATA",1130580001.101,58,6,0)
+^1130580001.111^4^4^3110430^^
+"DATA",1130580001.101,58,6,1,0)
+Percentage of patients aged 5 through 40 years with a 
+"DATA",1130580001.101,58,6,2,0)
+diagnosis of mild, moderate, or severe persistent asthma who were 
+"DATA",1130580001.101,58,6,3,0)
+prescribed either the preferred long-term control medication (inhaled 
+"DATA",1130580001.101,58,6,4,0)
+corticosteroid) or an acceptable alternative treatment
+"DATA",1130580001.101,58,7)
+NQF0047
+"DATA",1130580001.101,59,0)
+MU EP NQF 0001
+"DATA",1130580001.101,59,1)
+Asthma Assessment
+"DATA",1130580001.101,59,5)
+Asthma Assessment 
+"DATA",1130580001.101,59,6,0)
+^^5^5^3110430^
+"DATA",1130580001.101,59,6,1,0)
+Percentage of patients aged 5 through 40 years with a 
+"DATA",1130580001.101,59,6,2,0)
+diagnosis of asthma and who have been seen for at least 2 office 
+"DATA",1130580001.101,59,6,3,0)
+visits, who were evaluated during at least one office visit within 12 
+"DATA",1130580001.101,59,6,4,0)
+months for the frequency (numeric) of daytime and nocturnal asthma 
+"DATA",1130580001.101,59,6,5,0)
+symptoms.
+"DATA",1130580001.101,59,7)
+NQF0001
+"DATA",1130580001.101,60,0)
+MU EP NQF 0002
+"DATA",1130580001.101,60,1)
+Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer 
+"DATA",1130580001.101,60,5)
+Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer 
+"DATA",1130580001.101,60,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,60,6,1,0)
+Percentage of female patients aged 18 years and older 
+"DATA",1130580001.101,60,6,2,0)
+with Stage IC through IIIC, ER or PR positive breast cancer who were 
+"DATA",1130580001.101,60,6,3,0)
+prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month 
+"DATA",1130580001.101,60,6,4,0)
+reporting period.
+"DATA",1130580001.101,60,7)
+NQF0002
+"DATA",1130580001.101,61,0)
+MU EP NQF 0385
+"DATA",1130580001.101,61,1)
+Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients 
+"DATA",1130580001.101,61,5)
+Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients 
+"DATA",1130580001.101,61,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,61,6,1,0)
+Percentage of patients aged 18 years and older with 
+"DATA",1130580001.101,61,6,2,0)
+Stage IIIA through IIIC colon cancer who are referred for adjuvant 
+"DATA",1130580001.101,61,6,3,0)
+chemotherapy, prescribed adjuvant chemotherapy, or have previously 
+"DATA",1130580001.101,61,6,4,0)
+received adjuvant chemotherapy within the 12-month reporting period
+"DATA",1130580001.101,61,7)
+NQF0385
+"DATA",1130580001.101,62,0)
+MU EP NQF 0389
+"DATA",1130580001.101,62,1)
+Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients 
+"DATA",1130580001.101,62,5)
+Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients 
+"DATA",1130580001.101,62,6,0)
+^^5^5^3110430^
+"DATA",1130580001.101,62,6,1,0)
+Percentage of patients, regardless of age, with a diagnosis of 
+"DATA",1130580001.101,62,6,2,0)
+prostate cancer at low risk of recurrence receiving interstitial prostate 
+"DATA",1130580001.101,62,6,3,0)
+brachytherapy, OR external beam radiotherapy to the prostate, OR radical 
+"DATA",1130580001.101,62,6,4,0)
+prostatectomy, OR cryotherapy who did not have a bone scan performed at 
+"DATA",1130580001.101,62,6,5,0)
+any time since diagnosis of prostate cancer.
+"DATA",1130580001.101,62,7)
+NQF0389
+"DATA",1130580001.101,63,0)
+MU EP NQF 0027
+"DATA",1130580001.101,63,1)
+Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising 
+"DATA",1130580001.101,63,5)
+Smoking and Tobacco Use Cessation
+"DATA",1130580001.101,63,6,0)
+^^5^5^3110430^
+"DATA",1130580001.101,63,6,1,0)
+Percentage of patients 18 years of age and older who were 
+"DATA",1130580001.101,63,6,2,0)
+current smokers or tobacco users, who were seen by a practitioner during 
+"DATA",1130580001.101,63,6,3,0)
+the measurement year and who received advice to quit smoking or  tobacco
+"DATA",1130580001.101,63,6,4,0)
+use or whose practitioner recommended or discussed smoking or tobacco use
+"DATA",1130580001.101,63,6,5,0)
+cessation medications, methods or strategies
+"DATA",1130580001.101,63,7)
+NQF0027
+"DATA",1130580001.101,64,0)
+MU EP NQF 0055
+"DATA",1130580001.101,64,1)
+Diabetes: Eye Exam
+"DATA",1130580001.101,64,5)
+Diabetes: Eye Exam
+"DATA",1130580001.101,64,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,64,6,1,0)
+Percentage of patients 18 -75 years of age with diabetes (type 1 
+"DATA",1130580001.101,64,6,2,0)
+or type 2) who had a retinal or dilated eye exam or a negative retinal 
+"DATA",1130580001.101,64,6,3,0)
+exam (no evidence of retinopathy) by an eye care professional
+"DATA",1130580001.101,64,7)
+NQF0055
+"DATA",1130580001.101,65,0)
+MU EP NQF 0062
+"DATA",1130580001.101,65,1)
+Diabetes: Urine Screening
+"DATA",1130580001.101,65,5)
+Diabetes: Urine Screening
+"DATA",1130580001.101,65,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,65,6,1,0)
+Percentage of patients 18 - 75 years of age with diabetes (type 1 
+"DATA",1130580001.101,65,6,2,0)
+or type 2) who had a nephropathy screening test or evidence of 
+"DATA",1130580001.101,65,6,3,0)
+nephropathy.
+"DATA",1130580001.101,65,7)
+NQF0062
+"DATA",1130580001.101,66,0)
+MU EP NQF 0056
+"DATA",1130580001.101,66,1)
+Diabetes:  Foot Exam
+"DATA",1130580001.101,66,5)
+Diabetes:  Foot Exam
+"DATA",1130580001.101,66,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,66,6,1,0)
+The percentage of patients aged 18 - 75 years with diabetes 
+"DATA",1130580001.101,66,6,2,0)
+(type 1 or type 2) who had a foot exam (visual inspection, sensory exam 
+"DATA",1130580001.101,66,6,3,0)
+with monofilament, or pulse exam).
+"DATA",1130580001.101,66,7)
+NQF0056
+"DATA",1130580001.101,67,0)
+MU EP NQF 0074
+"DATA",1130580001.101,67,1)
+Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
+"DATA",1130580001.101,67,5)
+Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
+"DATA",1130580001.101,67,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,67,6,1,0)
+Percentage of patients aged 18 years and older with a 
+"DATA",1130580001.101,67,6,2,0)
+diagnosis of CAD who were prescribed a lipid-lowering therapy (based 
+"DATA",1130580001.101,67,6,3,0)
+on current ACC/AHA guidelines).
+"DATA",1130580001.101,67,7)
+NQF0074
+"DATA",1130580001.101,68,0)
+MU EP NQF 0084
+"DATA",1130580001.101,68,1)
+Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
+"DATA",1130580001.101,68,5)
+Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
+"DATA",1130580001.101,68,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,68,6,1,0)
+Percentage of all patients aged 18 years and older with a 
+"DATA",1130580001.101,68,6,2,0)
+diagnosis of heart failure and paroxysmal or chronic atrial fibrillation 
+"DATA",1130580001.101,68,6,3,0)
+who were prescribed warfarin therapy.
+"DATA",1130580001.101,68,7)
+NQF0084
+"DATA",1130580001.101,69,0)
+MU EP NQF 0073
+"DATA",1130580001.101,69,1)
+Ischemic Vascular Disease (IVD):  Blood Pressure Management
+"DATA",1130580001.101,69,5)
+Ischemic Vascular Disease (IVD):  Blood Pressure Management
+"DATA",1130580001.101,69,6,0)
+^^11^11^3110430^
+"DATA",1130580001.101,69,6,1,0)
+Percentage of patients 18 years of age and older who 
+"DATA",1130580001.101,69,6,2,0)
+were discharged alive for acute myocardial infarction (AMI), coronary 
+"DATA",1130580001.101,69,6,3,0)
+artery bypass graft (CABG) or percutaneous transluminal coronary 
+"DATA",1130580001.101,69,6,4,0)
+Percentage of patients 18 years of age and older who 
+"DATA",1130580001.101,69,6,5,0)
+were discharged alive for acute myocardial infarction (AMI), coronary 
+"DATA",1130580001.101,69,6,6,0)
+artery bypass graft (CABG) or percutaneous transluminal coronary 
+"DATA",1130580001.101,69,6,7,0)
+angioplasty (PTCA) from January 1- November 1 of the year prior to 
+"DATA",1130580001.101,69,6,8,0)
+the measurement year, or who had a diagnosis of ischemic vascular 
+"DATA",1130580001.101,69,6,9,0)
+disease (IVD) during the measurement year and the year prior to the 
+"DATA",1130580001.101,69,6,10,0)
+measurement year and whose recent blood pressure is in control 
+"DATA",1130580001.101,69,6,11,0)
+(<140/90 mmHg).
+"DATA",1130580001.101,69,7)
+NQF0073
+"DATA",1130580001.101,70,0)
+MU EP NQF 0068
+"DATA",1130580001.101,70,1)
+Ischemic Vascular Disease (IVD):  Use of Aspirin or Another Antithrombotic 
+"DATA",1130580001.101,70,5)
+ Ischemic Vascular Disease (IVD):  Use of Aspirin or Another Antithrombotic 
+"DATA",1130580001.101,70,6,0)
+^^8^8^3110430^
+"DATA",1130580001.101,70,6,1,0)
+ Percentage of patients 18 years of age and older who were 
+"DATA",1130580001.101,70,6,2,0)
+discharged alive for acute myocardial infarction (AMI), coronary artery 
+"DATA",1130580001.101,70,6,3,0)
+bypass graft (CABG) or percutaneous transluminal coronary 
+"DATA",1130580001.101,70,6,4,0)
+angioplasty (PTCA) from January 1-November 1 of the year prior to the 
+"DATA",1130580001.101,70,6,5,0)
+measurement year, or who had a diagnosis of ischemic vascular 
+"DATA",1130580001.101,70,6,6,0)
+disease (IVD) during the measurement year and the year prior to the 
+"DATA",1130580001.101,70,6,7,0)
+measurement year and who had documentation of use of aspirin or 
+"DATA",1130580001.101,70,6,8,0)
+another antithrombotic during the measurement year
+"DATA",1130580001.101,70,7)
+NQF0068
+"DATA",1130580001.101,71,0)
+MU EP NQF 0004
+"DATA",1130580001.101,71,1)
+ Initiation and Engagement of Alcohol and Other Drug  Dependence Treatment:(a)Initiation,(b)Engagement 
+"DATA",1130580001.101,71,5)
+Initiation and Engagement of Alcohol and Other Drug  Dependence Treatment:(a) Initiation,(b) Engagement 
+"DATA",1130580001.101,71,6,0)
+^^6^6^3110430^
+"DATA",1130580001.101,71,6,1,0)
+The percentage of adolescent and adult patients with a new 
+"DATA",1130580001.101,71,6,2,0)
+episode of alcohol and other drug (AOD) dependence who initiate treatment 
+"DATA",1130580001.101,71,6,3,0)
+through an inpatient AOD admission, outpatient visit, intensive 
+"DATA",1130580001.101,71,6,4,0)
+outpatient encounter or partial hospitalization within 14 days of the
+"DATA",1130580001.101,71,6,5,0)
+diagnosis and who initiated treatment and who had two or more additional
+"DATA",1130580001.101,71,6,6,0)
+services with an AOD diagnosis within 30 days of the initiation visit.
+"DATA",1130580001.101,71,7)
+NQF0004
+"DATA",1130580001.101,72,0)
+MU EP NQF 0012
+"DATA",1130580001.101,72,1)
+Prenatal Care:  Screening for Human Immunodeficiency Virus (HIV)
+"DATA",1130580001.101,72,5)
+Prenatal Care:  Screening for Human Immunodeficiency Virus (HIV)
+"DATA",1130580001.101,72,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,72,6,1,0)
+Percentage of patients, regardless of age, who gave birth during 
+"DATA",1130580001.101,72,6,2,0)
+a 12-month period who were screened for HIV infection during the first or 
+"DATA",1130580001.101,72,6,3,0)
+second prenatal care visit.
+"DATA",1130580001.101,72,7)
+NQF0012
+"DATA",1130580001.101,73,0)
+MU EP NQF 0014
+"DATA",1130580001.101,73,1)
+Prenatal Care:  Anti-D Immune Globulin
+"DATA",1130580001.101,73,5)
+Prenatal Care:  Anti-D Immune Globulin 
+"DATA",1130580001.101,73,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,73,6,1,0)
+Percentage of D (Rh) negative, unsensitized patients, regardless 
+"DATA",1130580001.101,73,6,2,0)
+of age, who gave birth during a 12-month period who received anti-D 
+"DATA",1130580001.101,73,6,3,0)
+immune globulin at 26-30 weeks gestation.
+"DATA",1130580001.101,73,7)
+NQD0014
+"DATA",1130580001.101,74,0)
+MU EP NQF 0018
+"DATA",1130580001.101,74,1)
+Controlling High Blood Pressure
+"DATA",1130580001.101,74,5)
+Controlling High Blood Pressure
+"DATA",1130580001.101,74,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,74,6,1,0)
+The percentage of patients 18-85 years of age who had a 
+"DATA",1130580001.101,74,6,2,0)
+diagnosis of hypertension and whose BP was adequately controlled during 
+"DATA",1130580001.101,74,6,3,0)
+the measurement year 
+"DATA",1130580001.101,74,7)
+NQF0018
+"DATA",1130580001.101,75,0)
+MU EP NQF 0032
+"DATA",1130580001.101,75,1)
+Cervical Cancer Screening
+"DATA",1130580001.101,75,5)
+Cervical Cancer Screening
+"DATA",1130580001.101,75,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,75,6,1,0)
+Percentage of women 21-64 years of age, who received one or 
+"DATA",1130580001.101,75,6,2,0)
+more Pap tests to screen for cervical cancer
+"DATA",1130580001.101,75,7)
+NQF0032
+"DATA",1130580001.101,76,0)
+MU EP NQF 0033
+"DATA",1130580001.101,76,1)
+Chlamydia Screening for Women
+"DATA",1130580001.101,76,5)
+Chlamydia Screening for Women
+"DATA",1130580001.101,76,6,0)
+^^3^3^3110430^
+"DATA",1130580001.101,76,6,1,0)
+Percentage of women 15- 24 years of age who were identified as sexually
+"DATA",1130580001.101,76,6,2,0)
+active and who had at least one test for chlamydia during the measurement
+"DATA",1130580001.101,76,6,3,0)
+year.
+"DATA",1130580001.101,76,7)
+NQF0033
+"DATA",1130580001.101,77,0)
+MU EP NQF 0036
+"DATA",1130580001.101,77,1)
+Use of Appropriate Medications for Asthma
+"DATA",1130580001.101,77,5)
+Use of Appropriate Medications for Asthma
+"DATA",1130580001.101,77,6,0)
+^^4^4^3110430^
+"DATA",1130580001.101,77,6,1,0)
+Percentage of patients 5 - 50 years of age who were identified as having
+"DATA",1130580001.101,77,6,2,0)
+persistent asthma and were appropriately prescribed medication during the
+"DATA",1130580001.101,77,6,3,0)
+measurement year. Report three age stratifications (5-11 years, 12-50
+"DATA",1130580001.101,77,6,4,0)
+years, and total). 
+"DATA",1130580001.101,77,7)
+NQF0036
+"DATA",1130580001.101,78,0)
+MU EP NQF 0052
+"DATA",1130580001.101,78,1)
+Low Back Pain: Use of Imaging Studies
+"DATA",1130580001.101,78,5)
+Low Back Pain: Use of Imaging Studies
+"DATA",1130580001.101,78,6,0)
+^1130580001.111^3^3^3110430^^
+"DATA",1130580001.101,78,6,1,0)
+Percentage of patients with a primary diagnosis of low back pain 
+"DATA",1130580001.101,78,6,2,0)
+who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 
+"DATA",1130580001.101,78,6,3,0)
+days of diagnosis.
+"DATA",1130580001.101,78,7)
+NQF0052
+"DATA",1130580001.101,79,0)
+MU EP NQF 0075
+"DATA",1130580001.101,79,1)
+Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control 
+"DATA",1130580001.101,79,5)
+Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control 
+"DATA",1130580001.101,79,6,0)
+^^7^7^3110430^
+"DATA",1130580001.101,79,6,1,0)
+Percentage of patients 18 years of age and older who were discharged alive
+"DATA",1130580001.101,79,6,2,0)
+for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
+"DATA",1130580001.101,79,6,3,0)
+or percutaneous transluminal angioplasty (PTCA) from January 1-November1
+"DATA",1130580001.101,79,6,4,0)
+of the year prior to the measurement year, or who had a diagnosis of
+"DATA",1130580001.101,79,6,5,0)
+ischemic vascular disease (IVD) during the measurement year and the year
+"DATA",1130580001.101,79,6,6,0)
+prior to the measurement year and who had a complete lipid profile
+"DATA",1130580001.101,79,6,7,0)
+performed during the measurement year and whose LDL-C<100 mg/dL
+"DATA",1130580001.101,79,7)
+NQF0075
+"DATA",1130580001.101,80,0)
+MU EP NQF 0575
+"DATA",1130580001.101,80,1)
+Diabetes:  Hemoglobin A1c Control (<8.0%)
+"DATA",1130580001.101,80,5)
+Diabetes:  Hemoglobin A1c Control (<8.0%)
+"DATA",1130580001.101,80,6,0)
+^^2^2^3110430^
+"DATA",1130580001.101,80,6,1,0)
+The percentage of patients 18-75 years of age with diabetes 
+"DATA",1130580001.101,80,6,2,0)
+(type 1 or type 2) who had hemoglobin A1c <8.0%
+"DATA",1130580001.101,80,7)
+NQF0575
+"DATA",1130580001.101,81,0)
+MU EP NQF 0028B^104^103
+"DATA",1130580001.101,81,1)
+NQF0028B Preventive Care and Screening  Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention 
+"DATA",1130580001.101,81,5)
+NQF0028B Tobacco Use Assessment and Cessation Intervention
+"DATA",1130580001.101,81,6,0)
+^1130580001.111^7^7^3110625^^^^
+"DATA",1130580001.101,81,6,1,0)
+ Percentage of patients aged 18 years and  
+"DATA",1130580001.101,81,6,2,0)
+older who have been seen for at least 2 office visits who 
+"DATA",1130580001.101,81,6,3,0)
+were queried about tobacco use one or more times within 
+"DATA",1130580001.101,81,6,4,0)
+24 months  b. Percentage of patients aged 18 years and 
+"DATA",1130580001.101,81,6,5,0)
+older  identified as tobacco users within the past 24 
+"DATA",1130580001.101,81,6,6,0)
+months and have been seen for at least 2 office visits, 
+"DATA",1130580001.101,81,6,7,0)
+who received cessation intervention.
+"DATA",1130580001.101,81,7)
+NQF0028B
+"DATA",1130580001.101,82,0)
+MU EP 0028B
+"DATA",1130580001.101,83,0)
+NQF0038 NUM1 DPT^115^109
+"DATA",1130580001.101,83,5)
+NQF0038 NUM1 DPT
+"DATA",1130580001.101,83,7)
+NQF0038 NUM1 DPT
+"DATA",1130580001.101,84,0)
+NQF0038 NUM2 IPV^123^109
+"DATA",1130580001.101,84,5)
+NQF0038 NUM2 IPV
+"DATA",1130580001.101,84,7)
+NQF0038 NUM2 IPV
+"DATA",1130580001.101,85,0)
+NQF0038 NUM3 MMR^114^109
+"DATA",1130580001.101,85,5)
+NQF0038 NUM3 MMR
+"DATA",1130580001.101,85,7)
+NQF0038 NUM3 MMR
+"DATA",1130580001.101,86,0)
+NQF0038 NUM4 HiB^116^109
+"DATA",1130580001.101,86,5)
+NQF0038 NUM4 HiB
+"DATA",1130580001.101,86,7)
+NQF0038 NUM4 HiB
+"DATA",1130580001.101,87,0)
+NQF0038 NUM5 HEP B^117^109
+"DATA",1130580001.101,87,5)
+NQF0038 NUM5 HEP B
+"DATA",1130580001.101,87,7)
+NQF0038 NUM5 HEP B
+"DATA",1130580001.101,88,0)
+NQF0038 NUM6 VZV^118^109
+"DATA",1130580001.101,88,5)
+NQF0038 NUM6 VZV
+"DATA",1130580001.101,88,7)
+NQF0038 NUM6 VZV
+"DATA",1130580001.101,89,0)
+NQF0038 NUM7 PCV^119^109
+"DATA",1130580001.101,89,5)
+NQF0038 NUM7 PCV
+"DATA",1130580001.101,89,7)
+NQF0038 NUM7 PCV
+"DATA",1130580001.101,90,0)
+NQF0038 NUM8 HEP A^120^109
+"DATA",1130580001.101,90,5)
+NQF0038 NUM8 HEP A
+"DATA",1130580001.101,90,7)
+NQF0038 NUM8 HEP A
+"DATA",1130580001.101,91,0)
+NQF0038 NUM9^121^109
+"DATA",1130580001.101,91,5)
+NQF0038 NUM9
+"DATA",1130580001.101,91,7)
+NQF0038 NUM9
+"DATA",1130580001.101,92,0)
+NQF0038 NUM10^122^109
+"DATA",1130580001.101,92,5)
+NQF0038 NUM10
+"DATA",1130580001.101,92,7)
+NQF0038 NUM10
+"DATA",1130580001.101,93,0)
+NQF0038 NUM11 COMBO5^124^109
+"DATA",1130580001.101,93,5)
+NQF0038 NUM11 COMBO5
+"DATA",1130580001.101,93,7)
+NQF0038 NUM11 COMBO5
+"DATA",1130580001.101,94,0)
+NQF0038 NUM12 COMBO6^125^109
+"DATA",1130580001.101,94,5)
+NQF0038 NUM12 COMBO6
+"DATA",1130580001.101,94,7)
+NQF0038 NUM12 COMBO6
+"DATA",1130580001.101,95,0)
+MU 2011 INP ADV DIRECTIVES
+"DATA",1130580001.101,95,5)
+Advance Directives
+"DATA",1130580001.101,95,7)
+^15^14^^17
+"DATA",1130580001.101,96,0)
+MU 2011 INP CPOE
+"DATA",1130580001.101,96,5)
+CPOE for Medications
+"DATA",1130580001.101,96,7)
+^10^30^^11
+"DATA",1130580001.101,97,0)
+MU 2011 INP MED RECON
+"DATA",1130580001.101,97,5)
+Medication Reconcilliation
+"DATA",1130580001.101,97,7)
+^19^21^^20
+"DATA",1130580001.101,98,0)
+MU 2011 INP PROBLEM LIST
+"DATA",1130580001.101,98,5)
+Problem List
+"DATA",1130580001.101,98,7)
+^27^30^^29
+"DATA",1130580001.101,99,0)
+MU 2011 INP VITAL SIGNS
+"DATA",1130580001.101,99,5)
+Record Vital Signs
+"DATA",1130580001.101,99,7)
+^16^30^^18
+"DATA",1130580001.101,100,0)
+MU 2011 INP SMOKING STATUS
+"DATA",1130580001.101,100,5)
+Smoking Status
+"DATA",1130580001.101,100,7)
+^12^30^^13
+"DATA",1130580001.101,101,0)
+MU 2011 INP MED LIST
+"DATA",1130580001.101,101,5)
+Active Medication List
+"DATA",1130580001.101,101,7)
+^26^30^^5
+"DATA",1130580001.101,102,0)
+MU 2011 INP ALLERGY LIST
+"DATA",1130580001.101,102,5)
+Medication Allergy List
+"DATA",1130580001.101,102,7)
+^24^30^^28
+"DATA",1130580001.101,103,0)
+MU 2011 INP DEMOGRAPHICS
+"DATA",1130580001.101,103,5)
+Record Demographics
+"DATA",1130580001.101,103,7)
+^25^30^^9
+"FIA",1130580001.101)
+C0Q QUALITY MEASURE
+"FIA",1130580001.101,0)
+^C0Q(101,
+"FIA",1130580001.101,0,0)
+1130580001.101I
+"FIA",1130580001.101,0,1)
+y^y^f^^n^^y^m^y
+"FIA",1130580001.101,0,10)
+
+"FIA",1130580001.101,0,11)
+
+"FIA",1130580001.101,0,"RLRO")
+
+"FIA",1130580001.101,1130580001.101)
+0
+"FIA",1130580001.101,1130580001.111)
+0
+"IX",1130580001.101,1130580001.101,"MU",0)
+1130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
+"IX",1130580001.101,1130580001.101,"MU",1)
+S ^C0Q(101,"MU",$E(X,1,30),DA)=""
+"IX",1130580001.101,1130580001.101,"MU",2)
+K ^C0Q(101,"MU",$E(X,1,30),DA)
+"IX",1130580001.101,1130580001.101,"MU",2.5)
+K ^C0Q(101,"MU")
+"IX",1130580001.101,1130580001.101,"MU",11.1,0)
+^.114IA^1^1
+"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
+1^F^1130580001.101^.3^30^1^F
+"MBREQ")
+0
+"QUES","XPF1",0)
+Y
+"QUES","XPF1","??")
+^D REP^XPDH
+"QUES","XPF1","A")
+Shall I write over your |FLAG| File
+"QUES","XPF1","B")
+YES
+"QUES","XPF1","M")
+D XPF1^XPDIQ
+"QUES","XPF2",0)
+Y
+"QUES","XPF2","??")
+^D DTA^XPDH
+"QUES","XPF2","A")
+Want my data |FLAG| yours
+"QUES","XPF2","B")
+YES
+"QUES","XPF2","M")
+D XPF2^XPDIQ
+"QUES","XPI1",0)
+YO
+"QUES","XPI1","??")
+^D INHIBIT^XPDH
+"QUES","XPI1","A")
+Want KIDS to INHIBIT LOGONs during the install
+"QUES","XPI1","B")
+NO
+"QUES","XPI1","M")
+D XPI1^XPDIQ
+"QUES","XPM1",0)
+PO^VA(200,:EM
+"QUES","XPM1","??")
+^D MG^XPDH
+"QUES","XPM1","A")
+Enter the Coordinator for Mail Group '|FLAG|'
+"QUES","XPM1","B")
+
+"QUES","XPM1","M")
+D XPM1^XPDIQ
+"QUES","XPO1",0)
+Y
+"QUES","XPO1","??")
+^D MENU^XPDH
+"QUES","XPO1","A")
+Want KIDS to Rebuild Menu Trees Upon Completion of Install
+"QUES","XPO1","B")
+NO
+"QUES","XPO1","M")
+D XPO1^XPDIQ
+"QUES","XPZ1",0)
+Y
+"QUES","XPZ1","??")
+^D OPT^XPDH
+"QUES","XPZ1","A")
+Want to DISABLE Scheduled Options, Menu Options, and Protocols
+"QUES","XPZ1","B")
+NO
+"QUES","XPZ1","M")
+D XPZ1^XPDIQ
+"QUES","XPZ2",0)
+Y
+"QUES","XPZ2","??")
+^D RTN^XPDH
+"QUES","XPZ2","A")
+Want to MOVE routines to other CPUs
+"QUES","XPZ2","B")
+NO
+"QUES","XPZ2","M")
+D XPZ2^XPDIQ
+"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
+
+"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
+@
+"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
+@
+"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
+@
+"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
+@
+"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
+@
+"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
+@
+"VER")
+8.0^22.0
+"^DD",1130580001.101,1130580001.101,0)
+FIELD^^.3^15
+"^DD",1130580001.101,1130580001.101,0,"DDA")
+N
+"^DD",1130580001.101,1130580001.101,0,"DT")
+3111201
+"^DD",1130580001.101,1130580001.101,0,"ID",.7)
+W:$D(^(5)) "   ",$P(^(5),U,1)
+"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
+
+"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
+
+"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
+
+"^DD",1130580001.101,1130580001.101,.01,0)
+NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
+"^DD",1130580001.101,1130580001.101,.01,.1)
+MEASURE NAME
+"^DD",1130580001.101,1130580001.101,.01,1,0)
+^.1
+"^DD",1130580001.101,1130580001.101,.01,1,1,0)
+1130580001.101^B
+"^DD",1130580001.101,1130580001.101,.01,1,1,1)
+S ^C0Q(101,"B",$E(X,1,30),DA)=""
+"^DD",1130580001.101,1130580001.101,.01,1,1,2)
+K ^C0Q(101,"B",$E(X,1,30),DA)
+"^DD",1130580001.101,1130580001.101,.01,3)
+Answer must be 1-30 characters in length
+"^DD",1130580001.101,1130580001.101,.01,"DT")
+3101012
+"^DD",1130580001.101,1130580001.101,.3,0)
+MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
+"^DD",1130580001.101,1130580001.101,.3,.1)
+MEANINGFUL USE YEAR KEY
+"^DD",1130580001.101,1130580001.101,.3,3)
+Answer must be 1-30 characters in length.
+"^DD",1130580001.101,1130580001.101,.3,"DT")
+3111201
+"^DD",1130580001.101,1130580001.101,.5,0)
+TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
+"^DD",1130580001.101,1130580001.101,.5,.1)
+MEASURE TITLE
+"^DD",1130580001.101,1130580001.101,.5,3)
+Answer must be 3-240 characters in length
+"^DD",1130580001.101,1130580001.101,.5,"DT")
+3110430
+"^DD",1130580001.101,1130580001.101,.61,0)
+VERY LONG DESCRIPTION^1130580001.111^^6;0
+"^DD",1130580001.101,1130580001.101,.7,0)
+DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
+"^DD",1130580001.101,1130580001.101,.7,.1)
+QRDA DISPLAY NAME
+"^DD",1130580001.101,1130580001.101,.7,3)
+Answer must be 3-240 characters in length
+"^DD",1130580001.101,1130580001.101,.7,"DT")
+3101012
+"^DD",1130580001.101,1130580001.101,.8,0)
+REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
+"^DD",1130580001.101,1130580001.101,.8,.1)
+REPORTING MEASURE NAME
+"^DD",1130580001.101,1130580001.101,.8,3)
+Answer must be 3-30 characters in length
+"^DD",1130580001.101,1130580001.101,.8,"DT")
+3110615
+"^DD",1130580001.101,1130580001.101,1,0)
+NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
+"^DD",1130580001.101,1130580001.101,1,.1)
+MEASURE NUMERATOR PATIENT LIST
+"^DD",1130580001.101,1130580001.101,1,"DT")
+3101012
+"^DD",1130580001.101,1130580001.101,1.1,0)
+ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
+"^DD",1130580001.101,1130580001.101,1.1,"DT")
+3110805
+"^DD",1130580001.101,1130580001.101,1.5,0)
+NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
+"^DD",1130580001.101,1130580001.101,1.5,.1)
+LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
+"^DD",1130580001.101,1130580001.101,1.5,"DT")
+3110809
+"^DD",1130580001.101,1130580001.101,1.51,0)
+ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
+"^DD",1130580001.101,1130580001.101,1.51,.1)
+NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
+"^DD",1130580001.101,1130580001.101,1.51,"DT")
+3110809
+"^DD",1130580001.101,1130580001.101,2,0)
+DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
+"^DD",1130580001.101,1130580001.101,2,.1)
+MEASURE DENOMINATOR PATIENT LIST
+"^DD",1130580001.101,1130580001.101,2,"DT")
+3101012
+"^DD",1130580001.101,1130580001.101,2.1,0)
+ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
+"^DD",1130580001.101,1130580001.101,2.1,"DT")
+3110805
+"^DD",1130580001.101,1130580001.101,3,0)
+QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
+"^DD",1130580001.101,1130580001.101,3,.1)
+MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
+"^DD",1130580001.101,1130580001.101,3,3)
+Answer must be 3-120 characters in length
+"^DD",1130580001.101,1130580001.101,3,"DT")
+3101012
+"^DD",1130580001.101,1130580001.101,3.1,0)
+QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
+"^DD",1130580001.101,1130580001.101,3.1,.1)
+QRDA SYSTEM OID (FIXED)
+"^DD",1130580001.101,1130580001.101,3.1,9.01)
+
+"^DD",1130580001.101,1130580001.101,3.1,9.1)
+S X="2.16.840.1.113883.3.249.12"
+"^DD",1130580001.101,1130580001.101,3.1,"DT")
+3101012
+"^DD",1130580001.101,1130580001.101,3.2,0)
+QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
+"^DD",1130580001.101,1130580001.101,3.2,.1)
+QRDA MEASURE CODE
+"^DD",1130580001.101,1130580001.101,3.2,3)
+Answer must be 1-80 characters in length
+"^DD",1130580001.101,1130580001.101,3.2,"DT")
+3101012
+"^DD",1130580001.101,1130580001.111,0)
+VERY LONG DESCRIPTION SUB-FIELD^^.01^1
+"^DD",1130580001.101,1130580001.111,0,"DT")
+3101013
+"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
+
+"^DD",1130580001.101,1130580001.111,0,"UP")
+1130580001.101
+"^DD",1130580001.101,1130580001.111,.01,0)
+VERY LONG DESCRIPTION^Wx^^0;1
+"^DD",1130580001.101,1130580001.111,.01,.1)
+LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
+"^DD",1130580001.101,1130580001.111,.01,3)
+LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
+"^DD",1130580001.101,1130580001.111,.01,"DT")
+3101013
+"^DIC",1130580001.101,1130580001.101,0)
+C0Q QUALITY MEASURE^1130580001.101
+"^DIC",1130580001.101,1130580001.101,0,"GL")
+^C0Q(101,
+"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
+
+**END**
+**END**